Premium
Discovery of biomarker candidates for coronary artery disease from an APOE‐knock out mouse model using iTRAQ‐based multiplex quantitative proteomics
Author(s) -
Jing Linhong,
Parker Carol E.,
Seo David,
Hines Maria Warren,
Dicheva Nedyalka,
Yu Yanbao,
Schwinn Debra,
Ginsburg Geoffrey S.,
Chen Xian
Publication year - 2011
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201000202
Subject(s) - multiplex , proteomics , biomarker , biomarker discovery , computational biology , apolipoprotein e , biology , disease , bioinformatics , medicine , pathology , gene , genetics
Abstract Due to the lack of precise markers indicative of its occurrence and progression, coronary artery disease (CAD), the most common type of heart diseases, is currently associated with high mortality in the United States. To systemically identify novel protein biomarkers associated with CAD progression for early diagnosis and possible therapeutic intervention, we employed an iTRAQ‐based quantitative proteomic approach to analyze the proteome changes in the plasma collected from a pair of wild‐type versus apolipoprotein E knockout (APOE −/− ) mice which were fed with a high fat diet. In a multiplex manner, iTRAQ serves as the quantitative ‘in‐spectra’ marker for ‘cross‐sample’ comparisons to determine the differentially expressed/secreted proteins caused by APOE knock‐out. To obtain the most comprehensive proteomic data sets from this CAD‐associated mouse model, we applied both MALDI and ESI‐based mass spectrometric (MS) platforms coupled with two different schemes of multidimensional liquid chromatography (2‐D LC) separation. We then comparatively analyzed a series of the plasma samples collected at 6 and 12 wk of age after the mice were fed with fat diets, where the 6‐ or 12‐wk time point represents the early or intermediate phase of the fat‐induced CAD, respectively. We then categorized those proteins showing abundance changes in accordance with APOE depletion. Several proteins such as the γ and β chains of fibrinogen, apolipoprotein B, apolipoprotein C‐I, and thrombospondin‐4 were among the previously known CAD markers identified by other methods. Our results suggested that these unbiased proteomic methods are both feasible and a practical means of discovering potential biomarkers associated with CAD progression.